Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
Cue Biopharma, Inc. (CUE) will participate in three investor conferences this November to provide a corporate overview, including recent data highlights from its lead clinical programs, CUE-101 and CUE-102, representative of the IL-2-based CUE-100 series of selective T cell engagers.
11/07/2023 - 08:00 AM
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will participate in three investor conferences this November, the Stifel Healthcare Conference, to be held in New York from November 14-15, the Jefferies London Healthcare Conference, to be held in London from November 14-16, and the Piper Sandler Annual Healthcare Conference, to be held in New York from November 28-30.
During the presentations and fireside discussions, Cue Biopharma will provide a corporate overview including recent data highlights from its lead clinical programs, CUE-101 and CUE-102, representative of the IL-2-based CUE-100 series of selective T cell engagers.
Presentation Details Stifel Healthcare Conference Date and Time: Tuesday, November 14 from 1:50 p.m. EST–2:20 p.m. ESTWebcast Link: https://wsw.com/webcast/stifel83/cue/1910858 Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
Jefferies London Healthcare Conference Date and Time: Thursday, November 16 from 11:00 a.m. GMT–11:25 a.m. GMTWebcast Link: https://wsw.com/webcast/jeff287/cue/1695916 Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
Piper Sandler 35th Annual Healthcare Conference Date and Time: Wednesday, November 29 at 4:00 p.m. EST–4:25 p.m. ESTWebcast Link: https://event.webcasts.com/starthere.jsp?ei=1642969&tp_key=a3f15c0417 Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
Live and archived webcasts of the presentations and fireside chats will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com . The webcasts will be archived for 30 days.
About Cue Biopharma Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma .
Investor Contact Marie Campinell Senior Director, Corporate Communications Cue Biopharma, Inc.mcampinell@cuebio.com
Media Contact Maya Romanchuk LifeSci Communicationsmromanchuk@lifescicomms.com
Cue Biopharma, Inc. (CUE) is announcing its participation in three investor conferences to provide a corporate overview, including recent data highlights from its lead clinical programs, CUE-101 and CUE-102, representative of the IL-2-based CUE-100 series of selective T cell engagers.
The Stifel Healthcare Conference will be held in New York from November 14-15, the Jefferies London Healthcare Conference will be held in London from November 14-16, and the Piper Sandler Annual Healthcare Conference will be held in New York from November 28-30.
Daniel Passeri, M.Sc., J.D., chief executive officer of Cue Biopharma, will be presenting at the conferences.
The webcasts will be available on the Events page in the Investors and Media section of Cue Biopharma's website at www.cuebiopharma.com. The webcasts will be archived for 30 days.
Cue Biopharma Inc
NASDAQ:CUE
CUE Rankings
#3994 Ranked by Stock Gains
CUE Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
Country
US
City
Cambridge
About CUE
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci